AI Article Synopsis

  • The study aimed to evaluate the endometrial safety of an oral contraceptive with estradiol valerate/dienogest (E(2)V/DNG) in women aged 18-50 through endometrial biopsy assessments.
  • A subgroup of women followed a specific regimen of E(2)V and DNG over a 28-day cycle, with biopsies taken at the beginning and after 20 cycles to monitor endometrial health.
  • Results showed no signs of harmful changes in the endometrium after 20 cycles, indicating that E(2)V/DNG is safe for transforming the endometrium without adverse histological effects.

Article Abstract

Background: The purpose of this study was to investigate the endometrial safety of an oral contraceptive containing estradiol valerate/dienogest (E(2)V/DNG) administered as an estrogen step-down and progestogen step-up regimen in women of reproductive age (18-50 years), using histological assessment of endometrial biopsy samples.

Methods: Endometrial biopsies were taken in a subset of healthy women who took part in a multicenter, open-label, noncomparative study assessing the contraceptive efficacy and safety of an E(2)V/DNG oral contraceptive. In each 28-day cycle, women received E(2)V 3 mg on days 1-2, E(2)V 2 mg/DNG 2 mg on days 3-7, E(2)V 2 mg/DNG 3 mg on days 8-24, E(2)V 1 mg on days 25-26, and placebo on days 27-28. Women underwent endometrial biopsy between days 12 and 19 of the cycle, both at screening and at cycle 20 (or at the final examination).

Results: Of the 283 women who underwent an endometrial biopsy at screening, 218 underwent a follow-up biopsy at cycle 20. At screening, abnormal biopsy results, both classified as "simple hyperplasia without atypia", were seen in two women, who were withdrawn from the trial. At cycle 20, there were no abnormal findings of endometrial hyperplasia or malignancy, and 80.9% of women had atrophic, inactive, or secretory endometrium.

Conclusion: After 20 cycles of treatment, an oral contraceptive containing E(2)V and DNG is safe and effective to transform the endometrium into a secretory/inactive or atrophic status, and exhibits no deleterious effects on endometrial histology in women aged 18-50 years.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3089431PMC
http://dx.doi.org/10.2147/IJWH.S18735DOI Listing

Publication Analysis

Top Keywords

oral contraceptive
16
endometrial biopsy
12
endometrial
8
endometrial safety
8
safety oral
8
contraceptive estradiol
8
women
8
18-50 years
8
e2v days
8
e2v mg/dng
8

Similar Publications

The study focuses on spontaneous conception after menopause in a woman with primary ovarian insufficiency (POI), with an emphasis on the role of anti-Müllerian hormone (AMH) in fertility management. This case involves a 33-year-old woman with POI who has experienced both aided and spontaneous pregnancies. She had low AMH and high follicle-stimulating hormone (FSH) levels, which typically indicate a limited ovarian reserve.

View Article and Find Full Text PDF

Introduction: For women of reproductive age, oral contraceptives (OCs) are a well-liked and practical way to control pregnancy. OCs are also used to treat acne, irregular uterine bleeding, and premenstrual syndrome. However, there are false beliefs regarding their benefits and risks.

View Article and Find Full Text PDF

Ischemic stroke is a major cause of mortality and disability and has become a significant public health concern among women. Overall, women have more ischemic stroke events than men, in part due to their longer life span, and also suffer from more severe stroke-related disabilities compared to men. Women are also more likely than men to present with atypical non-focal neurological symptoms, potentially leading to delayed diagnosis and treatment.

View Article and Find Full Text PDF

FSH/LH co-stimulation in Advanced Maternal Age (AMA) and hypo-responder patients - Arabian gulf delphi consensus group.

Front Endocrinol (Lausanne)

December 2024

The Fertility Clinic, Skive Regional Hospital, Skive, Department of Clinical Medicine, Aarhus University, Skive, Denmark.

Background: In a global effort to assess expert perspectives on the use of recombinant gonadotropins, recombinant human luteinizing hormone (r-hLH) and recombinant human follicle-stimulating hormone (r-hFSH), a consensus meeting was held in Dubai. The key aim was to address three critical questions: What are the factors that influence follicle response to gonadotropins? Which categories of patients are most likely to benefit from LH supplementation? And what are the optimal management strategies for these patients?

Methods: A panel of thirty-six experts reviewed and refined the initial statements and references proposed by the Scientific Coordinator. Consensus was defined as agreement or disagreement by more than two-thirds (66%) of the panel members for each statement.

View Article and Find Full Text PDF

Introduction Overturning Roe v. Wade left many concerned about birth control options and future fertility. This study aims to report Google (Google, Inc.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!